Last reviewed · How we verify
LTC004
At a glance
| Generic name | LTC004 |
|---|---|
| Sponsor | Letolab |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy (PHASE2)
- Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma (PHASE1, PHASE2)
- Phase II Clinical Study of LTC004 in Patients With mCRC (PHASE1, PHASE2)
- Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC (PHASE2)
- A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor (PHASE1)
- Clinical Trial for Advanced or Metastatic Pancreatic Cancer (PHASE2)
- Study of LTC004 in Subjects With Advanced Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTC004 CI brief — competitive landscape report
- LTC004 updates RSS · CI watch RSS
- Letolab portfolio CI